B-cell maturation antigen (BCMA) is a member of the tumor necrosis factor (TNF) receptor superfamily.1 Preclinical studies have shown that BCMA may play a role in the persistence of plasma cells and is universally expressed on the surface of both normal and malignant plasma cells.1-3 Therefore, BCMA is a promising target antigen in multiple myeloma.1,2
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
Seckinger A, et al. Cancer Cell. 2017;31:396-410.
Tai Y, Anderson K. Immunotherapy. 2015;7:1187-1199.
O’Connor BP, et al. J Exp Med. 2004;199:91-98.
Sign Up for Our Newsletter
To view To return to www.researchoncology.com